Inbiomotion unravelling the enigma of breast cancer
The economics newspaper Expansión Catalunya has echoed the forthcoming publication of the results of a clinical assay of the MAF-Test, a diagnostic test for breast cancer patients developed by Inbiomotion, a spin-off from IRB Barcelona set up in 2010 by the researcher Roger Gomis. The results are expected to be out in November. This test may have the capacity to identify those breast cancer patients who would benefit from treatment with bisphosphonates, a class of drugs used to treat non-metastatic breast cancer, but whose administration can in many cases be counterproductive. If the results are positive, it is hoped that this test will reduce mortality from the disease by 31%.
Related content
News
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.
The newspaper ABC has reported on a new project to be launched by IRB Barcelona researcher Roger Gomis thanks to a grant from the Fundación Fero y Mango. Focusing on luminal breast cancer, one of the most common subtypes, the project aims to decipher the “dialogue” between tumour cells and bone stem cells. This information can then be used to design therapeutic targets and to limit the capacity of these cells to metastasize. “This is a groundbreaking approach to tackle metastasis in this kind of cancer,” says Gomis.
The funded project will address the development of metastasis in breast cancer.
The grant, which is specifically for research into breast cancer, has been given by the foundation, in collaboration with Mango.
Fero is a private foundation that promotes translational cancer research in Spain.
